Payment overview · 2025
General Payments
$400.60
21 reported records · 6 companies
Healthcare provider profile · identity verified
Vijay Kumar, MD,FCCP
Allopathic & Osteopathic Physicians|Internal Medicine · SIMI VALLEY, CA · NPI 1689638587
Verified facts
What the public records show
CMS Open Payments records show Vijay Kumar, MD,FCCP received $400.60 in general payments during 2025 across 21 reported records.
Viatris Specialty LLC accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $182.41 | 45.5% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.57 | 17.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.32 | 16.3% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $48.31 | 12.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.32 | 4.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.67 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $400.60 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $182.41 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.57 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.32 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $48.31 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 627 | 156 |
| Atorvastatin Calcium | Atorvastatin Calcium | 527 | 95 |
| Eliquis | Apixaban | 516 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 494 | 76 |
| Gabapentin | Gabapentin | 337 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 324 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 319 | 131 |
| Furosemide | Furosemide | 310 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 250 | 39 |
| Metformin Hcl | Metformin Hcl | 238 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 40 |
| Prednisone | Prednisone | 177 | 86 |
| Trazodone Hcl | Trazodone Hcl | 174 | 33 |
| Losartan Potassium | Losartan Potassium | 160 | 32 |
| Buspirone Hcl | Buspirone Hcl | 144 | 31 |
| Potassium Chloride | Potassium Chloride | 140 | 32 |
| Breo Ellipta | Fluticasone/Vilanterol | 135 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 26 |
| Famotidine | Famotidine | 133 | 24 |
| Omeprazole | Omeprazole | 130 | 26 |
| Simvastatin | Simvastatin | 130 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 27 |
| Donepezil Hcl | Donepezil Hcl | 121 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 117 | 17 |
| Levetiracetam | Levetiracetam | 115 | 14 |
| Lisinopril | Lisinopril | 115 | 31 |
| Carvedilol | Carvedilol | 108 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 16 |
| Finasteride | Finasteride | 105 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 104 | 32 |
| Celecoxib | Celecoxib | 100 | 23 |
| Azithromycin | Azithromycin | 98 | 66 |
| Mirtazapine | Mirtazapine | 95 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 22 |
| Alendronate Sodium | Alendronate Sodium | 93 | 23 |
| Alprazolam | Alprazolam | 92 | 19 |
| Sertraline Hcl | Sertraline Hcl | 86 | 16 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 81 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 17 |
| Lacosamide | Lacosamide | 78 | suppressed |
| Spironolactone | Spironolactone | 73 | 13 |
| Midodrine Hcl | Midodrine Hcl | 72 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 69 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 14 |
| Jardiance | Empagliflozin | 66 | suppressed |
| Xarelto | Rivaroxaban | 66 | 13 |
| Glipizide | Glipizide | 64 | 17 |
| Ozempic | Semaglutide | 62 | suppressed |
| Allopurinol | Allopurinol | 61 | 20 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Lorazepam | Lorazepam | 58 | 13 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 33 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 55 | suppressed |
| Nystatin | Nystatin | 55 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 25 |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Tramadol Hcl | Tramadol Hcl | 43 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Roflumilast | Roflumilast | 41 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 40 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 37 | 14 |
| Humulin R | Insulin Regular, Human | 36 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 14 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 36 | suppressed |
| Novolin R | Insulin Regular, Human | 35 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 20 |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 16 |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 13 |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Clobazam | Clobazam | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | 11 |
| Valsartan | Valsartan | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Ofev | Nintedanib Esylate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 15 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Opsumit | Macitentan | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.60 · 21 records | Viatris Specialty LLC | Arikayce, BREZTRI, JOURNAVX, Korlym, WINREVAIR, YUPELRI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error